{"id":44859,"date":"2022-06-08T18:01:47","date_gmt":"2022-06-08T16:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/"},"modified":"2022-06-08T18:01:47","modified_gmt":"2022-06-08T16:01:47","slug":"enrollment-completed-in-onwards-lift-home-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/","title":{"rendered":"Enrollment Completed in ONWARD\u2019s LIFT Home Study"},"content":{"rendered":"
\n

\nStudy Evaluates Safety and Performance of ARCEX<\/sup> Therapy for Spinal Cord Injury in Home Setting<\/i>\n<\/p>\n

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the completion of enrollment in the LIFT Home Study. The trial is designed to study the safety and performance of ARCEX <\/sup>Therapy when used in the home.\n<\/p>\n

<\/a><\/p>\n

\nONWARD\u2019s ARCEX<\/sup> Therapy is externally delivered programmed stimulation of the spinal cord to restore strength and function in people with spinal cord injury and other movement related challenges. The study enrolled 17 participants at 5 leading research centers in the United States: Craig Hospital in Denver, Colorado, Shepherd Center in Atlanta, Georgia, Spaulding Research Institute in Boston, Massachusetts, University of Minnesota, and University of Washington. Subjects were followed for four weeks to assess whether continued access to ONWARD\u2019s ARCEX<\/sup> Therapy is safe and can be used to enhance long-term benefit.\n<\/p>\n

\nCandy Tefertiller, PT, DPT, Ph.D., NCS, Executive Director of Research and Evaluation at Denver\u2019s Craig Hospital served as Primary Investigator. \u201cThe LIFT Home Study is an important next step in understanding the potential benefits people with spinal cord injury may derive from continued access to ARC Therapy outside the clinic,\u201d said Dr. Tefertiller. \u201dWe are pleased enrollment is now complete and we look forward to completing follow-up activities.\u201d\n<\/p>\n

\nThe LIFT Home Study is a successor to ONWARD\u2019s Up-LIFT Study, a pivotal trial that completed enrollment of 65 participants in December 2021, with participating research centers in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate ONWARD ARCEX<\/sup> Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting. The LIFT Home Study seeks to evaluate the potential impact of ARCEX<\/sup> Therapy when used in the home setting.\n<\/p>\n

\n\u201cWe are grateful to collaborate with these outstanding researchers to investigate new potential benefits and care settings for our ARCEX<\/sup> Therapy,\u201d said Dave Marver, CEO of ONWARD. \u201cThis is another step in our journey to help people with spinal cord injury regain function and independence.\u201d\n<\/p>\n

\nTo learn more about ONWARD\u2019s ARC Therapy and the company\u2019s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com<\/a>.\n<\/p>\n

\nAbout ONWARD<\/b>\n<\/p>\n

\nONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD\u2019s work builds on more than a decade of basic science and preclinical research conducted at the world\u2019s leading neuroscience laboratories. ONWARD\u2019s ARC Therapy, which can be delivered by implantable (ARCIM<\/sup>) or external (ARCEX<\/sup>) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM <\/sup>and ARCEX<\/sup>. The company\u2019s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide. The company completed first-in-human use of its ARCIM<\/sup> neurostimulator in May 2022.\n<\/p>\n

\nONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com<\/a>. To access our 2022 Financial Calendar, please visit IR.ONWD.com<\/a>.\n<\/p>\n

\nDisclaimer<\/b>\n<\/p>\n

\nCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors\u2019 current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person\u2019s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Company Enquiries:
\n
info@onwd.com<\/a><\/p>\n

For Media Enquiries:
\n
Andy Dolan
\n
media@onwd.com<\/a>
+1.508.649.8466<\/p>\n

For Investor Enquiries:
\n
investors@onwd.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Study Evaluates Safety and Performance of ARCEX Therapy for Spinal Cord Injury in Home Setting EINDHOVEN, the Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the completion of enrollment in the LIFT Home … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44859","6":"format-standard","7":"category-industry"},"yoast_head":"\nEnrollment Completed in ONWARD\u2019s LIFT Home Study - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enrollment Completed in ONWARD\u2019s LIFT Home Study - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Study Evaluates Safety and Performance of ARCEX Therapy for Spinal Cord Injury in Home Setting EINDHOVEN, the Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the completion of enrollment in the LIFT Home ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-08T16:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220608005784\/en\/1428542\/21\/ONWARD_Logotype%E2%84%A2_Red.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enrollment Completed in ONWARD\u2019s LIFT Home Study\",\"datePublished\":\"2022-06-08T16:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/\"},\"wordCount\":874,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005784\\\/en\\\/1428542\\\/21\\\/ONWARD_Logotype%E2%84%A2_Red.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/\",\"name\":\"Enrollment Completed in ONWARD\u2019s LIFT Home Study - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005784\\\/en\\\/1428542\\\/21\\\/ONWARD_Logotype%E2%84%A2_Red.jpg\",\"datePublished\":\"2022-06-08T16:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005784\\\/en\\\/1428542\\\/21\\\/ONWARD_Logotype%E2%84%A2_Red.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005784\\\/en\\\/1428542\\\/21\\\/ONWARD_Logotype%E2%84%A2_Red.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enrollment-completed-in-onwards-lift-home-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enrollment Completed in ONWARD\u2019s LIFT Home Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enrollment Completed in ONWARD\u2019s LIFT Home Study - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/","og_locale":"en_US","og_type":"article","og_title":"Enrollment Completed in ONWARD\u2019s LIFT Home Study - Pharma Trend","og_description":"Study Evaluates Safety and Performance of ARCEX Therapy for Spinal Cord Injury in Home Setting EINDHOVEN, the Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the completion of enrollment in the LIFT Home ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-08T16:01:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220608005784\/en\/1428542\/21\/ONWARD_Logotype%E2%84%A2_Red.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enrollment Completed in ONWARD\u2019s LIFT Home Study","datePublished":"2022-06-08T16:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/"},"wordCount":874,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220608005784\/en\/1428542\/21\/ONWARD_Logotype%E2%84%A2_Red.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/","url":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/","name":"Enrollment Completed in ONWARD\u2019s LIFT Home Study - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220608005784\/en\/1428542\/21\/ONWARD_Logotype%E2%84%A2_Red.jpg","datePublished":"2022-06-08T16:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220608005784\/en\/1428542\/21\/ONWARD_Logotype%E2%84%A2_Red.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220608005784\/en\/1428542\/21\/ONWARD_Logotype%E2%84%A2_Red.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enrollment-completed-in-onwards-lift-home-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enrollment Completed in ONWARD\u2019s LIFT Home Study"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44859"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44859\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}